Nanomedicine in non-small cell lung cancer: From conventional treatments to immunotherapy

Coral García-Fernández, Cristina Fornaguera, Salvador Borrós

Producción científica: Artículo en revista indizadaRecensiónrevisión exhaustiva

28 Citas (Scopus)

Resumen

Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.

Idioma originalInglés
Número de artículo1609
Páginas (desde-hasta)1-26
Número de páginas26
PublicaciónCancers
Volumen12
N.º6
DOI
EstadoPublicada - jun 2020

Huella

Profundice en los temas de investigación de 'Nanomedicine in non-small cell lung cancer: From conventional treatments to immunotherapy'. En conjunto forman una huella única.

Citar esto